Papillary immature metaplasia of the anal canal: A low-grade lesion that can mimic a high-grade lesion

JM Roberts; AM Cornall; D Ekman; C Law; IM Poynten; F Jin; RJ Hillman; DJ Templeton; SN Tabrizi; SM Garland; JK Thurloe; AE Grulich; A Farnsworth

Journal article

Papillary immature metaplasia of the anal canal: A low-grade lesion that can mimic a high-grade lesion

JM Roberts, AM Cornall, D Ekman, C Law, IM Poynten, F Jin, RJ Hillman, DJ Templeton, SN Tabrizi, SM Garland, JK Thurloe, AE Grulich, A Farnsworth

American Journal of Surgical Pathology | Published : 2016

DOI: 10.1097/PAS.0000000000000549

Abstract

In a natural history study of anal human papillomavirus (HPV) infection and HPV-related lesions among homosexual men in Sydney, Australia, we identified 15 examples of papillary immature metaplasia (PIM) in anal biopsy samples. PIM has previously been described in the cervix, but not in the anal canal. PIM is a form of exophytic low-grade squamous intraepithelial lesion (eLSIL) also known as condyloma. In contrast to the maturing keratinocytes and koilocytosis seen in conventional eLSIL, the slender papillary structures of PIM have a surface population of immature squamous cells. In our anal samples PIM was characterized by close proximity to conventional eLSIL, was negative for p16INK4A (p1..

View full abstract

University of Melbourne Researchers

Suzanne Wark Author

Related Projects (2)

SEXUALLY TRANSMITTED INFECTIONS: CAUSES, CONSEQUENCES AND INTERVENTIONS

Sexually transmitted infections are important causes of serious illness and death in Australia and overseas with high or rising rates of tre..

DISCOVERY AND TRANSLATION OF INTERVENTIONS TO CONTROL SEXUALLY TRANSMITTED INFECTIONS AND THEIR CONSEQUENCES

Sexually transmitted infections are important causes of illness and death in Australia and globally. Populations particularly affected in Au..

Grants

Awarded by NHMRC

Awarded by Cancer Council NSW Strategic Research Partnership Program

Awarded by National Health and Medical Research Council

Awarded by National Health and Medical Research Council of Australia

Funding Acknowledgements

The Study of the Prevention of Anal Cancer is funded by NHMRC program grants (# 568971 and # 1071269) and a Cancer Council NSW Strategic Research Partnership Program grant (# 13-11). Cytological testing materials are provided by Hologic (Australia) Pty Ltd. I.M.P. (# 1016307) and D.J.T. (# 1013353) are supported by Post-doctoral Training Fellowships from the National Health and Medical Research Council. R.J.H. has received advisory board fees, grant support, and travel assistance from Gilead, CSL, and Merck. S.M.G. has received advisory board fees and grant support from CSL and GlaxoSmithKline, and lecture fees from Merck, GSK, and Sanofi Pasteur; in addition, she has also received funding through her institution to conduct HPV vaccine studies for MSD and GSK. She is a member of the Merck Global Advisory Board as well as the Merck Scientific Advisory Committee for HPV. For the remaining authors none were declared.